ASP Isotopes Inc. 8-K

What Happened

• ASP Isotopes Inc. announced the closing of its previously disclosed acquisition of Renergen Limited on January 6, 2026. Under a scheme of arrangement pursuant to the South African Companies Act, ASP acquired all issued ordinary shares of Renergen in exchange for ASP Isotopes common stock. Renergen is a company focused on liquefied helium (LHe) and liquefied natural gas (LNG) production.
• The exchange ratio was 0.09196 ASP Isotopes shares for each Renergen ordinary share, resulting in the issuance of 14,270,000 consideration shares. Fractional share entitlements were rounded and paid in cash where applicable. As a result, Renergen became a direct, wholly owned subsidiary of ASP Isotopes.

Key Details

• Closing date: January 6, 2026; press release issued January 7, 2026 (Exhibit 99.2).
• Exchange ratio: 0.09196 ASP shares per Renergen share; total Consideration Shares issued: 14,270,000.
• Renergen ordinary shares will be delisted from the Johannesburg Stock Exchange (JSE), the Australian Securities Exchange (ASX) and A2X; ASP Isotopes common stock remains listed on The Nasdaq Global Market and on the JSE.
• Executive appointments: Stefano Marani (former Renergen CEO) named President, Electronics and Space; Nick Mitchell (former Renergen COO) named Co‑Chief Operating Officer.

Why It Matters

• The transaction expands ASP Isotopes’ business into Renergen’s LHe and LNG operations and makes Renergen a wholly owned subsidiary, which may materially change the company’s operations and asset base. Investors should note the issuance of 14.27 million new shares (dilution effect) and the maintenance of ASP’s Nasdaq and JSE listings.
• The filing also highlights standard acquisition-related risks (integration, disruption, transaction costs, potential litigation, IP protection and growth management) in its forward‑looking statements section, reminding investors that outcomes may differ from expectations. Review the full 8-K and prior announcements for more detail.